(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Pick the Right Toothbrush for Your Teeth - 2Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
- 3The Best Internet based Courses for Expertise Improvement
- 4How AI fixed the James Webb Space Telescope's blurry vision
- 5Step by step instructions to Figure out the Natural Effect of 5G Pinnacles
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- Smooth out Your Funds: Cash The board Simplified
- Malaysia To Revive Search for Missing Flight MH370
- Well known Tea Brands for Each Tea Sweetheart
- Find the Captivating Professional flowerbeds of the US
- Monetary Freedom Guide: Plan Your Future
- The Main 15 Powerful Business Heads of Today
- Vote in favor of your Favored kind of craftsmanship
- Effectiveness Uncovered: A Survey of \Smoothing out Your Errands\ Efficiency Application
